246 related articles for article (PubMed ID: 33790905)
1. Novel Human Tenascin-C Function-Blocking Camel Single Domain Nanobodies.
Dhaouadi S; Ben Abderrazek R; Loustau T; Abou-Faycal C; Ksouri A; Erne W; Murdamoothoo D; Mörgelin M; Kungl A; Jung A; Ledrappier S; Benlasfar Z; Bichet S; Chiquet-Ehrismann R; Hendaoui I; Orend G; Bouhaouala-Zahar B
Front Immunol; 2021; 12():635166. PubMed ID: 33790905
[TBL] [Abstract][Full Text] [Related]
2. Generation and characterization of dromedary Tenascin-C and Tenascin-W specific antibodies.
Dhaouadi S; Murdamoothoo D; Tounsi A; Erne W; Benabderrazek R; Benlasfar Z; Hendaoui L; Chiquet-Ehrismann R; Boubaker S; Orend G; Hendaoui I; Bouhaouala-Zahar B
Biochem Biophys Res Commun; 2020 Sep; 530(2):471-478. PubMed ID: 32593416
[TBL] [Abstract][Full Text] [Related]
3. Modulating tenascin-C functions by targeting the MAtrix REgulating MOtif, "MAREMO".
Loustau T; Abou-Faycal C; Erne W; Zur Wiesch PA; Ksouri A; Imhof T; Mörgelin M; Li C; Mathieu M; Salomé N; Crémel G; Dhaouadi S; Bouhaouala-Zahar B; Koch M; Orend G
Matrix Biol; 2022 Apr; 108():20-38. PubMed ID: 35227929
[TBL] [Abstract][Full Text] [Related]
4. Isolation and characterization of nanobodies against epithelial cell adhesion molecule as novel theranostic agents for cancer therapy.
Roshan R; Naderi S; Behdani M; Cohan RA; Ghaderi H; Shokrgozar MA; Golkar M; Kazemi-Lomedasht F
Mol Immunol; 2021 Jan; 129():70-77. PubMed ID: 33183767
[TBL] [Abstract][Full Text] [Related]
5. Production and Characterization of Novel Camel Single Domain Antibody Targeting Mouse Vascular Endothelial Growth Factor.
Kazemi-Lomedasht F; Behdani M; Habibi-Anbouhi M; Shahbazzadeh D
Monoclon Antib Immunodiagn Immunother; 2016 Jun; 35(3):167-71. PubMed ID: 27167350
[TBL] [Abstract][Full Text] [Related]
6. Proteomic Profiling of Extracellular Matrix Components from Patient Metastases Identifies Consistently Elevated Proteins for Developing Nanobodies That Target Primary Tumors and Metastases.
Jailkhani N; Clauser KR; Mak HH; Rickelt S; Tian C; Whittaker CA; Tanabe KK; Purdy SR; Carr SA; Hynes RO
Cancer Res; 2023 Jun; 83(12):2052-2065. PubMed ID: 37098922
[TBL] [Abstract][Full Text] [Related]
7. Fenobody and RANbody-based sandwich enzyme-linked immunosorbent assay to detect Newcastle disease virus.
Ji P; Zhu J; Li X; Fan W; Liu Q; Wang K; Zhao J; Sun Y; Liu B; Zhou EM; Zhao Q
J Nanobiotechnology; 2020 Mar; 18(1):44. PubMed ID: 32169061
[TBL] [Abstract][Full Text] [Related]
8. Tumor-derived tenascin-C promotes the epithelial-mesenchymal transition in colorectal cancer cells.
Takahashi Y; Sawada G; Kurashige J; Matsumura T; Uchi R; Ueo H; Ishibashi M; Takano Y; Akiyoshi S; Iwaya T; Eguchi H; Sudo T; Sugimachi K; Yamamoto H; Doki Y; Mori M; Mimori K
Anticancer Res; 2013 May; 33(5):1927-34. PubMed ID: 23645740
[TBL] [Abstract][Full Text] [Related]
9. Tenascin C induces epithelial-mesenchymal transition-like change accompanied by SRC activation and focal adhesion kinase phosphorylation in human breast cancer cells.
Nagaharu K; Zhang X; Yoshida T; Katoh D; Hanamura N; Kozuka Y; Ogawa T; Shiraishi T; Imanaka-Yoshida K
Am J Pathol; 2011 Feb; 178(2):754-63. PubMed ID: 21281808
[TBL] [Abstract][Full Text] [Related]
10. Development of oligoclonal nanobodies for targeting the tumor-associated glycoprotein 72 antigen.
Sharifzadeh Z; Rahbarizadeh F; Shokrgozar MA; Ahmadvand D; Mahboudi F; Rahimi Jamnani F; Aghaee Bakhtiari SH
Mol Biotechnol; 2013 Jun; 54(2):590-601. PubMed ID: 23015323
[TBL] [Abstract][Full Text] [Related]
11. Tenascin-C Function in Glioma: Immunomodulation and Beyond.
Yalcin F; Dzaye O; Xia S
Adv Exp Med Biol; 2020; 1272():149-172. PubMed ID: 32845507
[TBL] [Abstract][Full Text] [Related]
12. Tenascin-C enhances pancreatic cancer cell growth and motility and affects cell adhesion through activation of the integrin pathway.
Paron I; Berchtold S; Vörös J; Shamarla M; Erkan M; Höfler H; Esposito I
PLoS One; 2011; 6(6):e21684. PubMed ID: 21747918
[TBL] [Abstract][Full Text] [Related]
13. Oligoclonal selection of nanobodies targeting vascular endothelial growth factor.
Ahadi M; Ghasemian H; Behdani M; Kazemi-Lomedasht F
J Immunotoxicol; 2019 Dec; 16(1):34-42. PubMed ID: 30409071
[TBL] [Abstract][Full Text] [Related]
14. Spatial organization of the tenascin-C microenvironment in experimental and human cancer.
Spenlé C; Gasser I; Saupe F; Janssen KP; Arnold C; Klein A; van der Heyden M; Mutterer J; Neuville-Méchine A; Chenard MP; Guenot D; Esposito I; Slotta-Huspenina J; Ambartsumian N; Simon-Assmann P; Orend G
Cell Adh Migr; 2015; 9(1-2):4-13. PubMed ID: 25611571
[TBL] [Abstract][Full Text] [Related]
15. The Promoting Effect of the Extracellular Matrix Peptide TNIIIA2 Derived from Tenascin-C in Colon Cancer Cell Infiltration.
Suzuki H; Sasada M; Kamiya S; Ito Y; Watanabe H; Okada Y; Ishibashi K; Iyoda T; Yanaka A; Fukai F
Int J Mol Sci; 2017 Jan; 18(1):. PubMed ID: 28106752
[TBL] [Abstract][Full Text] [Related]
16. Development of multivalent nanobodies blocking SARS-CoV-2 infection by targeting RBD of spike protein.
Lu Q; Zhang Z; Li H; Zhong K; Zhao Q; Wang Z; Wu Z; Yang D; Sun S; Yang N; Zheng M; Chen Q; Long C; Guo W; Yang H; Nie C; Tong A
J Nanobiotechnology; 2021 Jan; 19(1):33. PubMed ID: 33514385
[TBL] [Abstract][Full Text] [Related]
17. Development of a highly sensitive immunoassay based on pentameric nanobodies for carcinoembryonic antigen detection.
Gu Y; Guo Y; Deng Y; Song H; Nian R; Liu W
Anal Chim Acta; 2023 Oct; 1279():341840. PubMed ID: 37827654
[TBL] [Abstract][Full Text] [Related]
18. Selection and characterization of camelid nanobodies towards urokinase-type plasminogen activator.
Kaczmarek JZ; Skottrup PD
Mol Immunol; 2015 Jun; 65(2):384-90. PubMed ID: 25749705
[TBL] [Abstract][Full Text] [Related]
19. Tumour-associated tenascin-C isoforms promote breast cancer cell invasion and growth by matrix metalloproteinase-dependent and independent mechanisms.
Hancox RA; Allen MD; Holliday DL; Edwards DR; Pennington CJ; Guttery DS; Shaw JA; Walker RA; Pringle JH; Jones JL
Breast Cancer Res; 2009; 11(2):R24. PubMed ID: 19405959
[TBL] [Abstract][Full Text] [Related]
20. Generation and characterization of non-competitive furin-inhibiting nanobodies.
Zhu J; Declercq J; Roucourt B; Ghassabeh GH; Meulemans S; Kinne J; David G; Vermorken AJ; Van de Ven WJ; Lindberg I; Muyldermans S; Creemers JW
Biochem J; 2012 Nov; 448(1):73-82. PubMed ID: 22920187
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
